Viewing Study NCT01358604


Ignite Creation Date: 2025-12-24 @ 8:03 PM
Ignite Modification Date: 2025-12-25 @ 5:36 PM
Study NCT ID: NCT01358604
Status: COMPLETED
Last Update Posted: 2016-04-15
First Post: 2011-05-18
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Biomarkers in Samples From Young Patients With Neuroblastoma
Sponsor: Children's Oncology Group
Organization:

Study Overview

Official Title: ROR1 as a Novel Target for Neuroblastoma
Status: COMPLETED
Status Verified Date: 2016-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE: Studying samples of tissue and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study studies biomarkers in samples from young patients with neuroblastoma.
Detailed Description: OBJECTIVES:

Primary

* To analyze the expression of ROR1 on the surface of primary neuroblastoma cells.
* To investigate the therapeutic potential of anti-ROR1 monoclonal antibodies (mAbs), bispecific antibodies, and immunotoxins in in vitro and in vivo models of neuroblastoma.

OUTLINE: Archived bone marrow and tumor tissue samples are analyzed for ROR1 expression by flow cytometry, western blotting, qPCR, and IHC.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
COG-ANBL11B2 OTHER Children's Oncology Group View
NCI-2011-02855 REGISTRY CTRP (Clinical Trial Reporting Program) View
ANBL11B2 OTHER Children's Oncology Group View